{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:20:39Z","timestamp":1760548839271},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ijrobp.2009.03.024","type":"journal-article","created":{"date-parts":[[2009,7,5]],"date-time":"2009-07-05T08:07:00Z","timestamp":1246781220000},"page":"1085-1091","source":"Crossref","is-referenced-by-count":5,"title":["Phase II Study of Vinorelbine and Estramustine in Combination With Conformational Radiotherapy for Patients With High-Risk Prostate Cancer"],"prefix":"10.1016","volume":"76","author":[{"given":"Joan","family":"Carles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Nogue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Sole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palmira","family":"Foro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferr\u00e1n","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Gelabert-Mas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Gayo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Fabregat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2009.03.024_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.2005.11.148","article-title":"Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis","volume":"23","author":"Brenner","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ijrobp.2009.03.024_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1464-410X.2007.07485.x","article-title":"Chemotherapy in hormone-refractory prostate cancer","volume":"101","author":"de Wit","year":"2008","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2009.03.024_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-suppl_1-4","article-title":"The ELVIS trial: A phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study","volume":"6","author":"Gridelli","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib4","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2003.06.099","volume":"21","author":"Gridelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib5","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/1097-0142(20011101)92:9<2267::AID-CNCR1572>3.0.CO;2-Q","article-title":"Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma","volume":"92","author":"Zelek","year":"2001","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2009.03.024_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.6-suppl_1-8","article-title":"Long term analysis of survival in the European randomized trial comparing vinorelbine\/cisplatin to vindesine\/cisplatin and vinorelbine alone in advanced non-small cell lung cancer","volume":"6","author":"Le Chevalier","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib7","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1023\/A:1008315106697","article-title":"Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial","volume":"10","author":"Fields-Jones","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib8","first-page":"13","article-title":"Estramustine-based chemotherapy","volume":"15","author":"Hudes","year":"1997","journal-title":"Semin Urol Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib9","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.1999.17.10.3160","article-title":"Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial","volume":"17","author":"Hudes","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.bjc.6601468","article-title":"Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer","volume":"90","author":"Albrecht","year":"2004","journal-title":"Br J\u00a0Cancer"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/028418698429757","article-title":"Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients","volume":"37","author":"Carles","year":"1998","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3816\/CGC.2004.n.020","article-title":"Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer","volume":"3","author":"Berry","year":"2004","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib13","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","article-title":"Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer","volume":"23","author":"Oudard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0360-3016(94)90455-3","article-title":"Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer","volume":"29","author":"Kim","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0360-3016(94)90524-X","article-title":"Estramustine: A novel radiation enhancer in human carcinoma cells","volume":"30","author":"Ryu","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1200\/JCO.1997.15.3.1013","article-title":"Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31","volume":"15","author":"Pilepich","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0360-3016(94)90011-6","article-title":"Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer","volume":"30","author":"Diaz","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib20","series-title":"Common toxicity criteria, version 2.0","author":"National Cancer Institute","year":"1999"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib21","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib22","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0360-3016(91)90732-J","article-title":"Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706","volume":"21","author":"Lawton","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02710012","article-title":"A phase II study of vinorelbine and estramustine in patients with hormone-resistant prostate cancer","volume":"7","author":"Carles Galceran","year":"2005","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1200\/JCO.1998.16.4.1318","article-title":"Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study","volume":"16","author":"Wendt","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib25","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1056\/NEJM199904153401501","article-title":"Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer","volume":"340","author":"Morris","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib26","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1200\/JCO.1997.15.5.2030","article-title":"Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114","volume":"15","author":"Tepper","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib27","first-page":"289","article-title":"Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy","volume":"3","author":"Khil","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0360-3016(00)01375-4","article-title":"Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results","volume":"49","author":"Ben-Josef","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib29","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.2004.02.001","article-title":"Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate","volume":"22","author":"Kumar","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib30","first-page":"225","article-title":"[Radiochemotherapy and simultaneous hormonal therapy of locally advanced prostatic carcinoma]","volume":"172","author":"Strnad","year":"1996","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib31","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.2000.18.9.1936","article-title":"Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer","volume":"18","author":"Zelefsky","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2004.03.006","article-title":"Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer","volume":"64","author":"Ryan","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib33","author":"Rosenthal","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib35","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/sj.bjc.6604030","article-title":"Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study","volume":"97","author":"Carles","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib36","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib37","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0360-3016(98)00091-1","article-title":"Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer","volume":"41","author":"Zelefsky","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2009.03.024_bib39","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ejca.2004.12.028","article-title":"Technological advances in radiotherapy for the treatment of localised prostate cancer","volume":"41","author":"Mangar","year":"2005","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609004593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301609004593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T07:09:53Z","timestamp":1558422593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301609004593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0360301609004593"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2009.03.024","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}